The Deerborne Group is a veteran owned and operated boutique management consulting firm comprised of industry leading consultants from across the globe that work together to help businesses achieve their objectives. It is our belief that consultants should have a long history and be “subject matter experts” in the field that they are consulting in. As such, our consultants come exclusively from biotechnology, in-vitro diagnostics, and the life sciences. They combine their extensive expertise with their first-hand knowledge to help our clients gain the strategic insights needed to identify and accelerate the development and commercialization of promising diagnostic solutions.
While we focus on biotechnology, in-vitro diagnostics, and the life sciences, in-vitro diagnostics is at the core of what we do. We have successfully taken dozens of tests and instruments through the FDA's 510K, PMA, and EUA process and we've also successfully developed and launched dozens of CE-IVD and laboratory developed tests (LDT's) as well. Technologies range from CLIA-waved point-of-care (POC) lateral flow tests to highly-complex next-generation sequencing tests (NGS). Disease states include infectious diseases, immunology, cardiology, women's health, cancer, and more. With a particular focus on cancer diagnostics, we've successfully commercialized dozens of liquid and solid tumor tests.
Our expertise includes market analysis, due-diligence, strategy development, portfolio planning, market access, advisory boards, product development, KOL development, clinical trials, regulatory strategy & submissions, publication planning, value propositions, branding, commercialization, sales operations effectiveness, reimbursement, health economics, CLIA laboratory operations, interim management services, venture capital and private equity strategy.